Professor Paul M. Vanhoutte
Dr. Vanhoutte used to be President of the International Union of Pharmacology (IUPHAR). Dr. Vanhoutte also serves as the Editor-in-Chief of the Journal of Cardiovascular Pharmacology , advisor to the Ministry of Science and Technology of the People's Republic of China , and Vice President of R&D of an international research organization in France . His academic career took him from the University of Ghent to the University of Antwerp, the Mayo Medical School and Baylor College of Medicine. He is currently a Distinguished Visiting Professor, and Director of the Biopharmaceutical Development Centre, at the University of Hong Kong . Dr. Vanhoutte has published over 500 original research papers, 474 book reviews, and authored or edited 3 books. In 2000 he was nominated for the Nobel Prize for his outstanding contributions to the field of cardiovascular disease.
Professor Barry H. Greenberg Dr. Greenberg is currently Professor of Medicine at UCSD School of Medicine and Director, Advanced Heart Failure Treatment Program at UCSD. He is also a charter member of the UCSD/Salk Institute of Molecular Medicine. He is a founding member and used to be Vice President of the Heart Failure Society of America. He is a member of the advisory board for Neucardin’s clinical trials. Dr. Greenberg leads an active research program investigating basic mechanisms and new treatment methods involved in heart failure. He serves on the Editorial Board for many famous cardiology journals and is an editor of the Congestive Heart Failure and an Associate editor of the Journal of the American College of Cardiology. Dr. Greenberg has been consistently selected as one of the "Best Doctors in America" for many years.
Professor Inder AnandDr. Anand received his Ph.D. degree in cardiovascular physiology from Oxford University and is the professor of University of Minnesota . He is the Chairman of heart failure group. He is the advisor of global clinical trials for Neucardin. He has been active in designing and conducting clinical trials in heart failure over the last twenty years. He has been a principal investigator in over 50 heart failure clinical trials, and member of steering and end-point committees of several of these international trials. He is member of the editorial board of several Journals and has authored over 300 scientific publications and has over 1,000 citations of his published work.
Robin AllgrenShe received her Ph.D. degree from Stanford University and MBA from Golden Gate University. She has more than 25 years industry experience, spanning biotech, pharma, medical devices and diagnostics. She successfully executed clinical development activities at all stages of development, from preclinical stage through IND filing, NDA filing and approval. She also has very rich experience in pharmacovigilance.